Pharmaceuticals
POMDOCTOR LIMITED Drive Internet Hospital Growth Through Strengthened Strategic Partnerships With Pharmaceutical Companies
GUANGZHOU, China, Jan. 16, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases inChina, today announced significant progress in its strategic collaboration with leading domestic pharmaceutical compani...
2026-01-16 22:00
672
Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held inSan Francisco, the United States, fromJanuary 12 to 15. As one of the most influential annual events in the global healthcare sector, JPM serves as a key platform for the capital...
2026-01-16 21:00
429
The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification
SHENZHEN, China, Jan. 15, 2026 /PRNewswire/ -- On January 7, 2026, the AKG and Ca-AKG of Xin Tianhe Biotechnology successfully completed the Self-GRAS scientific evaluation in accordance with the US FDA GRAS standards and were approved and became the first domestic fermentation products that obta...
2026-01-16 12:23
1127
Hugel accelerates global value creation with U.S.-led growth strategy
- President and Global CEO Carrie Strom outlines mid-term growth strategy including global vision, U.S. channel strategy, and portfolio expansion - Hugel targets KRW900 billion in total net sales and 30% of sales from U.S. by 2028 SAN FRANCISCO, Jan. 15, 2026 /PRNewswire/ -- Hugel, Inc., a leadin...
2026-01-16 08:00
1134
SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
HIGHLIGHTS * Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol. Patient population * With the SECuRE trial continuing to recruit, a total of n...
2026-01-15 22:02
1574
Recognition beyond borders: the life-long commitment of "Grandpa Sugar Pill"
BEIJING, Jan. 15, 2026 /PRNewswire/ -- A news report from China.org.cn on Gu Fangzhou, the father of sugar pills — a live oral polio vaccine:   Recognition beyond borders: the life-long commitment of "Grandpa Sugar Pill" Small, sweet, and slightly gritty when dissolved on the...
2026-01-15 22:00
1400
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects * 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients * Complex modalities are WuXi Biologics' core growth engi...
2026-01-15 12:00
1895
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. - Dr. Davey Smith: "With this multi-v...
2026-01-15 11:34
1531
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy for th...
2026-01-14 11:54
1417
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
* Celltrion outlines a blueprint for innovative drug development built on its antibody expertise * The company highlights its business strategy to scale U.S. manufacturing and R&D capabilities, strengthening its global supply chain, production and operations INCHEON, South Korea, Jan. 13, 202...
2026-01-14 09:18
1447
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral sclerosis (ALS). The initial dosing occurred at Second ...
2026-01-13 20:30
885
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, in patients with advanced gastric ...
2026-01-13 16:26
1307
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...
2026-01-13 11:07
597
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...
2026-01-13 11:07
450
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...
2026-01-13 08:54
411
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...
2026-01-13 08:54
438
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
* AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx * AbbVie will commit $100 billion in U.S. research and development (R&D) and capital investments, including manufacturing, over the nex...
2026-01-13 07:30
219
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"),
a clinical-stage, generative AI-driven drug discovery company, today announced
the completion of first patient first dose in BETHESDA: a Phase IIa clinical
trial of ISM5411 (NCT07265570
2026-01-12 21:30
314
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveragin...
2026-01-12 21:05
446
Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion
HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities BEIJING, Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an ex...
2026-01-12 20:00
365
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 310 media titles]
2026-01-15 13:00Colebrook Bosson Saunders Launches Lana: An Adaptable Laptop Stand Engineered for Hybrid Work
[Picked up by 305 media titles]
2026-01-12 16:16
Ready Server Announces Strategic Expansion into Japan with AT TOKYO Data Centre
[Picked up by 301 media titles]
2026-01-13 13:16
CAYIN AI: Revolutionizing Creativity and Global Communication
[Picked up by 300 media titles]
2026-01-12 16:34
JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 299 media titles]
2026-01-15 10:00Most Read
TCL Earns Multiple CES 2026 Awards for Breakthrough Innovations Across TV, Mobile, and Smart Home Categories
2026-01-10 01:00
5469
CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
2026-01-11 04:10
4364
